• Azithromycin, Roxithromycin and Senolytic Evidence

  2026-10-12

  Ozsvari et al. reported selective effects of azithromycin and roxithromycin against DNA-damage-induced senescent human fibroblasts in vitro. The findings support further investigation of macrolide-associated senolytic activity, but they do not establish clinical anti-aging efficacy or demonstrate that a single senescence biomarker is sufficient for senescent cell detection.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-10-10

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding target and degradation-sensitive protein for Bufalin in triple-negative breast cancer models. Its multi-layered evidence connects STK33 binding to CCAR1 stabilization, tumor-cell growth, and responses in cell, animal, and patient-derived organoid systems, while remaining preclinical rather than clinical evidence.

• MAPK10, KRT16, and NSCLC Metastasis

  2026-10-09

  A 2026 International Journal of Biological Macromolecules study identifies a MAPK10–KRT16–RNF213 pathway that links phosphorylation to ubiquitin-dependent degradation and suppression of non-small cell lung cancer metastasis. The findings provide a mechanistic framework for interpreting MAPK10 as a prognostic marker, while the small clinical sample and model-specific evidence limit immediate therapeutic extrapolation.

• Reversine: Product Identity and Evidence Limits

  2026-10-09

  Reversine is an APExBIO research product described as an Aurora kinase inhibitor for conceptual studies of mitotic regulation and cancer biology; no matched paper evidence is available here.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-10-08

  Gu et al. report that combining CDK4/6 inhibition with BET inhibition suppresses pancreatic ductal adenocarcinoma growth while counteracting the pro-invasive and EMT-associated effects observed with CDK4/6 inhibition alone. The study connects this response to GSK3β-mediated Wnt/β-catenin activity and crosstalk with TGF-β/Smad signaling, providing a mechanistic rationale for combination-focused PDAC research.

• DGLA–ACSL4 Ferroptosis in AML: Study Insights

  2026-10-08

  A 2025 Translational Oncology study identifies dihomo-γ-linolenic acid (DGLA) as a ferroptosis-inducing lipid in acute myeloid leukemia and places ACSL4 at the center of this response. The findings connect fatty-acid remodeling with leukemia-cell vulnerability, while remaining preclinical and requiring validation in patient-derived systems.

• Saracatinib and the Reelin–SFK Translational Bridge

  2026-10-07

  Saracatinib (AZD0530) offers a useful chemical lens for studying Src family kinase biology across cancer and neuroscience. This thought-leadership analysis connects vendor-reported oncology findings with a PNAS study showing that Reelin–Apoer2–SFK signaling permits ketamine-associated synaptic plasticity in mice, while defining the evidence boundaries that translational researchers should preserve.

• Moxifloxacin: From Gyrase to Cell Phenotype

  2026-10-07

  Moxifloxacin research is strongest when target-level evidence is separated from cellular and systemic phenotypes. This article applies a provenance-first framework to fluoroquinolone antibiotic mechanism, retinal-cell toxicity, and metabolic findings without overstating what each model can prove.

• Primidone: From Biomarker to Mechanism

  2026-10-06

  Primidone, also known as Mysoline, offers a valuable case study in how drug repurposing can connect RIPK1 biology, ALS biomarkers, and TRPM3-related disease research. This evidence-focused analysis separates reported mechanisms from translational claims and defines where the data remain preliminary.

• BI-1347 and CDK8/19: Translational Signals

  2026-10-06

  A source-grounded analysis of how CDK8/19 biology may inform translational research around BI-1347, while separating vendor-reported potency from validated target, cellular, and disease evidence.

• JEV, NS4B, and Lysosomal Dysfunction via LAMP1/2

  2026-10-05

  A 2024 Veterinary Microbiology study identifies a mechanistic link between Japanese encephalitis virus NS4B, ER-stress-associated autophagy, and loss of lysosomal integrity through reduced LAMP1 and LAMP2. The findings suggest that viral stimulation of autophagy can coexist with impaired terminal lysosomal degradation, while also affecting SLA-DR organization relevant to antigen presentation.

• 6-Thioguanine and EV71: BIRC3–Autophagy Evidence

  2026-10-04

  A 2025 BMC Microbiology study identifies 6-thioguanine as an in-vitro inhibitor of EV71 replication and links this activity to reduced BIRC3 expression and attenuation of complete autophagy. The findings support a mechanistic antiviral hypothesis, but the evidence remains limited to cell culture and does not establish clinical efficacy or therapeutic dosing.

• Vernakalant Hydrochloride: From Selectivity to Translation

  2026-10-03

  A source-grounded perspective on how Vernakalant Hydrochloride and its development code RSD1235 connect atrial ion-channel pharmacology with exposure–response modeling, clinical conversion outcomes, and a more disciplined translational strategy.

• PF-573228: FAK Signaling at the Matrix Edge

  2026-10-02

  A translational perspective on using PF-573228 to connect focal adhesion signaling, substrate mechanics, angiogenesis, cancer cell behavior, and dentinogenic differentiation.

• BML-277: Chk2 Assay Design & Interpretation

  2026-10-01

  BML-277 is a potent Chk2 inhibitor for resolving kinase-dependent DNA damage signaling. This assay-focused guide explains how to connect biochemical inhibition, T-cell radioprotection, and the nuclear Chk2–cGAS pathway without overinterpreting cellular results.

8037 records 1/536 page Next 12345 下5页 Last page